Dr. Daniel C. Chung appointed as Chief Medical Officer of SparingVision
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of…
New investors include 4BIO Capital, UPMC Enterprises, Jeito Capital and Ysios Capital with additional investment…
Paris, June 30th, 2020 – SparingVision, a biotechnology company specializing in the research and development…